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Summary Ninety-one lung cancer patients were evaluated to determine the usefulness of bone metabolic markers in the diagnosis and
follow-up of bone metastases and also to investigate their clinical usefulness as an adjunct to bone scintigraphy. Both bone resorption
markers, ICTP and fDPD, and bone formation markers, Al-p, BAL, PICP and BGP, were evaluated in 47 patients with and 44 without bone
metastasis. The patients with bone metastasis were classified according to the bone metastatic burden, and they were also separately
classified into groups according to the course of the bone metastasis. ICTP, fDPD, Al-p and BAL were significantly elevated (P < 0.001) in
patients with bone metastasis, but PICP and BGP were not. Receiver-operating characteristic (ROC) curves of these markers revealed that
ICTP was most highly correlated with the diagnosis of bone metastasis. The sensitivity of ICTP (71.4%) and fDPD (61.0%) were good with
high specificity. T scores of ICTP, fDPD and BAL tended to be higher at higher grades of bone metastasis. T-scores of ICTP, fDPD and BAL
were elevated in the newly diagnosed cases and progressed cases, but the T-scores of ICTP and fDPD in those cases were higher than that
of BAL. In the follow-up study, ICTP was well correlated with uncontrolled or controlled bone metastasis. Thus, bone resorption markers,
especially ICTP, could be a good indicator of the progression and multiplicity of disease, and it could help in the follow-up and in the
monitoring of therapy for bone metastasis from lung cancer.
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Metastatic bone tumours are the most common type of malignant
bone lesion seen in adults. Atpost-mortem, the prevalence ofbone
metastases from lung cancer was reported to range from 32% to
40% (Abrams et al, 1950). Although bone metastasis is usually
diagnosed based on imaging studies in which bone scintigraphy
plays a major role, false-negative scans may result when the lesion
is small, is rapidly growing or entirely osteolytic (Tubiana-Hulin,
1991). Bone metastases secondary to lung cancer are thought to be
predominantly osteolytic. False-negative scans are not uncommon
in lung cancer. False-positive scans also present problems in bone
scintigraphy in that hot spots are not always associated with bone
metastasis.
Recently, novel biochemical bone metabolic markers have been
identified and investigated in bone diseases (Garnero et al, 1994).
Bone metabolic markers have been reported to be of value in
investigating bone metastasis from breast cancer (Coleman et al,
1992; Blomqvist et al, 1996), prostate cancer (Miyamoto et al,
1994; Sano et al, 1994; Kylmala et al, 1995; Maeda et al, 1997)
and multiple myeloma (Elomaa et al, 1992). In this study, we
investigated the clinical value of bone metabolic markers for
detecting bone metastasis in patients with lung cancer.
PATIENTS AND METHODS
Ninety-one patients with lung cancer who visited the Department
ofNuclear Medicine for the assessment ofbone involvement were
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included in this study. There were 52 men and 39 women who
ranged in age from 29 to 77 years (mean 58.2 years). All patients
were evaluated for the presence or absence of bone metastasis by
bone scintigraphy. The patients who had humoral hypercalcaemia
associated with malignancy, hyperparathyroidism, hypopara-
thyroidism, hyperthyroidism, renal failure or traumatic fracture
(within 6 months) were excluded from this study. In the patients
who showed equivocal bone scintigraphic findings or a discrep-
ancy between symptoms and bone scintigraphic results, plain
radiography, computerized tomography and/or magnetic reso-
nance imaging were performed to confirm the presence or absence
of bone metastasis. Thus, the presence or absence of bone metas-
tasis was judged by clinical course, bone scintigraphy and other
imaging modalities. The extent of bone metastasis was classified
into three grades: grade 1, solitary lesion; grade 2, two to five
lesions; grade 3, six or more lesions (mainly based on a bone
scan). Whenever a bone scan was positive for bone metastasis, the
scan was compared with the previous scan in the same patient. The
patients were also subdivided into four groups: newly diagnosed
(NEW); improvement (IMP), which included those with a
decrease of more than 50% of bone lesions; no change (NC),
which included those with a decrease of less than 50% or a
progression ofless than 25%; and progression ofdisease (PROG),
which included those progressing more than 25% or showing new
lesions. In some patients with bone metastasis (followed-up
patients), other serum samples were also collected.
The sera and urinary samples were collected at the time of bone
scintigraphy and kept frozen at -400C until analysis. The urinary
sample was a spoturinetaken ataround 10.00 h. Theboneformation
markers used were procollagen I carboxy-terminal peptide (PICP),
total alkaline phosphatase (Al-p), bone-specific alkalinephosphatase
(BAL) and osteocalcin, which is the so-called bone-gla protein
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Table 1 Bone metabolic markers in lung cancer patients with and without bone metastasis
Bone resorption markers Bone formation markers
ICTPa fDPD' PICP BGP ALPa BALa
(ng ml-') (nmol mmol-' Cr) (ng ml-') (ng ml-') (IU 1-') (IU 1-')
Bone metastasis
Positive 8.2 ± 5.2 9.7 ± 6.1 124.7 ± 70.7 5.2 ± 4.0 338.6 ± 248.7 36.7 + 33.2
Negative 3.0 ± 1.2 4.5 ± 1.8 105.2 ± 35.4 6.1 ± 3.2 205.4 ± 83.1 19.8 ± 8.0
aThe values for patients with bone metastasis are high and are statistically significant compared with the values for patients without bone metastasis
(P< 0.001). Cr, creatinine.
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Figure 1 Receiver operating characteristic (ROC) curves of six markers:
ICTP(0), fDPD(0), BAL (A), Al-p (A), PICP (+) and BGP (X)
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Figure 2 T-scores of the bone metabolic markers ICTP, fDPD and BAL of
each grade divided into groups according to the extent of the bone
metastasis. Error bars represent one standard error of mean. *P< 0.001
compared with that of bone metastasis-negative patients. **P < 0.01.
Grade: E], one lesion; P, 2-5 lesions; O, six lesions or more
(BGP). The bone resorption markers used were pyridinoline cross-
linked carboxy-terminal telopeptide (ICTP) and the free form of
deoxypyridinoline (fDPD). PICP was measured using a radio-
immunoassay (PICP RIA kit, Orion Diagnostica, Epsoo, Finland).
Al-p was measured by using p-nitrophenyl phosphate substrate in
diethanolamine buffer at 37°C. BAL was measured using an enzyme
immunoassay (Alkphase-B kit, Metra Biosystems, CA, USA). BGP
was measured using an immunoradiometric assay using tracer anti-
BGP (12-33) antibody and solid-phase anti-BGP (30-49) antibody
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Figure 3 T-scores of the bone metabolic markers ICTP, fDPD and BAL of
each group subdivided according to the course of bone metastases, based
mainly on bone scintigraphy. Error bars represent one standard error of
mean. #P< 0.001 compared with that of bone metastasis-negative
patients.##0.01 < P< 0.05 compared with that of bone metastasis-negative
patients. *P < 0.001. **0.01 < P< 0.05. Change: L, IMP; e], NC; H, NEW;
*, PROG
with synthetic human BGP (1-49) as a standard (Mitsubishi BGP-
IRMAkit, Mitsubishi Chemical,Tokyo,Japan). ICTPwas measured
using a radioimmunoassay (ICTP RIA kit, Orion Diagnostica).
Urinary fDPD was measured using a direct enzyme-linked
immunoassay (Pyrilinks-D kit, Metra Biosystems, CA, USA) and
the result is expressed relative to urinarycreatinine.
The data are expressed as the mean ± s.d. or T-score with s.e.m.
Receiver-operating characteristic (ROC) curves were drawn in six
markers based on true-positive ratio and false-positive ratio. The T
score in patients with bone metastasis was calculated from the
mean ± s.d. ofpatients withoutbone metastasis. T-score = (value -
mean ofpatients without bone metastasis)/s.d. of patients without
bone metastasis.
The sensitivity and specificity was calculated using upper limits
ofreference intervals ofICTP 4.9 ng ml-', fDPD 7.3 nmol mmol-'
creatinine, PICP 140 ng ml-, BGP 9.9 ng ml-', Al-p 270 IU 1-1 at
37°C and BAL 30 U 1-' (Maeda et al, 1997). The sensitivity was
calculated as the number ofpatients who showed above the upper
limit of the reference interval of a marker with bone metastasis
divided by the numberofpatients with.bone metastasis. The speci-
ficity was calculated as the number ofpatients who showed within
reference interval of a marker without bone metastasis divided by
the number of patients without bone metastasis. The relation
(number of true- and false-positive and true- and false-negative
results) between bone scan results and ICTP results was obtained
based on abnormal uptake on bone scan and the upper limits of
reference intervals in ICTP measurement. The statistical analysis
was performed using the Mann-Whitney U-test or one-way
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Table 2 The sensitivity and specificity of bone metabolic markers in lung cancer patients
Bone resorption markers Bone formation markers
ICTP fDPD PICP BGP ALP BAL
(4.9 ng ml-')' (7.3 nmol mmol-' Cr)a (140 ng ml-')' (9.9 ng ml-')' (270 IU l-1)" (30 U l-')'
Sensitivity (%)
Total 71.4 (45/63) 61.0 (25/41) 28.6 (18/63) 12.3 (8/63) 55.6 (35/63) 44.4 (28/63)
NEWb 61.3 (19/31) 47.1 (8/17) 29.0 (9/31) 12.9 (4/31) 54.8 (17/31) 45.2 (14/31)
Specificity (%) 87.9 (25/33) 93.0 (40/43) 87.9 (29/33) 81.8 (36/44) 79.5 (35/44) 93.2 (41/44)
aUpper limit of reference interval. bNEW, patients who had newly diagnosed bone metastasis. Cr, creatinine.
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Figure 4 Serial measurement of ICTP was performed in a 49-year-old
woman with bone metastasis. Her bone metastasis had progressed despite
radiation therapy (RT), and the ICTP value was elevated continuously
ANOVA followed by Fisher's PLSD method. A P-value of less
than 0.05 was considered to be significant.
RESULTS
Of 91 patients with lung cancer, 47 had bone metastasis and 44
showed no overt bone metastasis. In 11 patients with bone metas-
tasis, follow-up studies were carried out. A total of63 studies with
bone metastasis and 44 studies without bone metastasis were eval-
uated. In the 63 studies with bone metastasis, 11 had grade 1, 24
had grade 2 and 28 had grade 3 bone metastasis. These 63 studies
were subdivided into 31 NEW, five IMP, eight NC and 19 PROG.
In the patients without overt bone metastasis, ICTP and PICP data
were not measured in 11 patients. fDPD was not measured in 25
patients with bone metastasis and one without bone metastasis.
As shown in Table 1, ICTP, fDPD, Al-P and BAL were signifi-
cantly higher in the patients with bone metastasis than those
without bone metastasis (P < 0.0001 for ICTP and fDPD,
P < 0.001 for BAL and Al-p, Mann-Whitney U-test). However,
there were no significant differences in PICP and BGP between
the patients with and without bone metastasis.
Figure 1 shows ROC curves of ICTP, fDPD and BAL. ICTP
showed the best curve characteristics among six markers, followed
by the fDPD and BAL curves. The Al-p curve showed a little
lower than the BAL curve. The PICP and BGP curves showed
poor characteristics. The distance of the ROC curves from the
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Figure 5 Serial measurement of ICTP was performed in a 48-year-old man
with bone metastasis in his right pelvis. The bone metastasis stayed
unchanged for 1 year, and the ICTP value was constant at the upper limit of
the reference interval
point (true-positive ratio = 1, false-positive ratio = 0) indicated
that ICTP at 4.2 ng ml', fDPD at 6.0 nmol mmol-' creatinine,
BAL at 25.0 U1-l, Al-p at 220 IU 1-', PICP at 120 ng ml-' and BGP
at 5.5 ng ml- gave the least-square values.
Figure 2 shows T-scores of bone metabolic markers of each
group divided according to the grade ofbone metastasis. T-scores
of markers tended to increase with the grade of metastasis. ICTP
and fDPD were elevated in all groups ofbone metastasis compared
with those ofpatients without bone metastasis, whereas BAL was
not elevated in the grade 1 patients. ICTP and fDPD showed
significant elevation in the patients with multiple lesions (grades 2
and 3) (P < 0.001).
Figure 3 shows T-scores of bone metabolic markers of each
group divided by the change in the extent ofbone metastasis rela-
tive to the previous study. All three bone metabolic markers were
significantly elevated when the first diagnosis of bone metastasis
was made and when it progressed. The values decreased with
improvement.
Because we wanted higher specificity, the higherupper limits of
the reference intervals were used rather than the values that were
obtained from the ROC curve distance from the point (true-posi-
tive ratio = 1, false-positive ratio = 0). Table 2 shows the sensi-
tivity and specificity of six markers. The sensitivities of bone
resorption markers ICTP (71.4%) and fDPD (61.0%) were supe-
rior to those ofbone formation markers. The sensitivities ofPICP
(28.6%) and BGP (12.3%), which are bone formation markers,
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Table 3 Comparison between bone scan and ICTP
Bone metastasis negative Bone metastasis positive
Bone scan (abnormal uptake)a Bone scan (abnormal uptake)a
ICTpb
- 15 14 1 17
+ 3 1 1 47
aBone scan (abnormal uptake) + indicates abnormal hot spots irrelevant to
their nature. bICTP: +, above reference value; -, below reference value.
were low; the specificities of PICP (87.9%) and BGP (81.8%)
were almost equal to those of ICTP (87.9%) and fDPD (93.0%).
The sensitivities of ICTP (61.3%) and fDPD (47.1%) in NEW
cases were slightly lower than those in the total patientpopulation.
Table 3 shows the relation between bone scan results and ICTP
measurement. In the patients without bone metastasis, 15 patients
showed positive scintigraphic findings and 14 of the 15 patients
had an ICTP value below the upper limit ofthe reference interval.
Two patients with bone metastasis had a negative bone scan, one
of them showed elevation of ICTP. The ICTP level of the other
patient (aged 37 years) was 4.5 ng ml-', which was within the
reference interval but high for his age. He showed elevation of
ICTPthereafter; 7.7 ng ml-' at 1 month later, 10.5 at 2 months later
and 31.4 at 3 months later.
Eleven patients were studied repeatedly. Ten patients showed
progression of bone metastasis, and they showed ICTP elevation
with the progression of bone metastasis (Figure 4). Bone metas-
tasis of one patient was controlled for 1 year, and the ICTP level
stayed around the upper limit ofthe reference interval (Figure 5).
DISCUSSION
Bone scintigraphy is one of the major modalities in the diagnosis
of bone metastasis. However, false-negative scans are thought to
be not uncommon in lung cancer. On the otherhand, false-positive
scans are also found in a number of benign conditions, such as
fractures and arthritis. Therefore, the finding of adjuncts to bone
scintigraphy in the diagnosis and follow-up of bone metastasis is
pressing. To this purpose, we investigated the possibility of bone
metabolic markers.
The elevation of bone resorption markers in patients with bone
metastasis was highly significant when compared with patients
without bone metastasis. The levels of bone formation markers,
such as PICP and BGP, however, were not significantly different
in those patients with and those without metastasis. Al-p and BAL,
which are also bone formation markers, showed statistically
significant elevation. This result is consistent with that ofa smaller
population in our previous report (Koizumi et al, 1995). The ROC
curve analysis revealed that ICTP gave the best ROC curve,
followed by fDPD and BAL curves. Using T-score analysis, ICTP
and fDPD showed higher values than that of BAL. T-scores of
ICTP and fDPD increased according to the increase of bone
metastatic burden. The T-score showed that, for three markers,
ICTP elevation was greater in patients with progression and newly
diagnosed bone metastasis. Thus, a finding of elevated ICTP
and/or fDPD concentration may be suggestive ofbone metastasis;
and very high values suggest that the bone tumourburden is large.
The sensitivities of ICTP and fDPD were good and were higher
than those of all the bone formation markers. The sensitivities of
ICTP (61.2%) and fDPD (47.1%) in the patients who were newly
diagnosed with bone metastasis showed slightly lower sensitivities
than the patient population as a whole. This could be explained by
the fact that the bone metastasis grades or bone tumourburdens of
NEW patients were lower than those in the total population.
The levels of bone formation markers, such as PICP and BGP,
were not significantly different in those patients with and those
without bone metastasis. Al-p and BAL, which are also bone
formation markers, showed statistically significant elevation. The
insensitivity of PICP and BGP could be derived from the osteo-
lytic nature of bone metastasis from lung cancer. The reason why
the dissociation ofbone formation markers (the elevation ofBAL
and Al-p and no significant change in PICP and BGP) was
presented in lung cancer patients with bone metastasis is not
known. We also investigated the bone formation markers PICP,
BAL and BGP in prostate cancer patients with and without bone
metastasis. In the prostate cancer patients with osteoblastic bone
metastasis, BAL showed the most significant elevation. PICP
showed significant elevation, but the degree of elevation was not
so high as that ofBAL. BGP did not show significant elevation in
prostate cancer (Koizumi et al, 1997). Even the patients with
osteoblastic bone metastasis showed discrepancies in the behav-
iour of bone formation markers. At present, we do not have an
explanation for these discrepancies in bone formation markers in
lung cancer bone metastasis.
Because Al-p is produced not only by osteoblasts but also by
various organs, such as the liver, small intestine and placenta, its
elevation is not specific to bone metastasis. BAL, which is an
isozyme of Al-p derived from bone, seems to be more specific in
bone metastasis than Al-p. Furthermore, BAL was superior to Al-
p in the ROC analysis. BAL seems to be superior to Al-p in the
diagnosis of bone metastasis in lung cancer, even though the
resorption markers, especially ICTP, are better than formation
markers for this purpose.
As shown in Table 3, bone scans often show false-positive
results because ofthe non-specific nature ofradionuclide uptake in
bone. In many cases, the patterns of uptake for benign conditions
can be differentiated by experienced physicians. However, in some
cases, it is difficult to judge the presence or absence of bone
metastasis using bone scan. In these cases, the measurement of
bone metabolic markers, in particular bone resorption markers,
may be clinically useful.
Follow-up or evaluation of the therapy for bone metastasis are
currently performed using imaging studies. As shown in Figures 2
and 3, ICTP correlated with the bone metastatic burden and
changes in bone metastasis. In the follow-up study shown in
Figures 4 and 5, the pattern of ICTP was significantly different
between uncontrolled and controlled bone metastasis. Bone meta-
bolic markers can help in the follow-up or in the monitoring of
therapy for bone metastasis from lung cancer.
In conclusion, bone resorption markers, such as ICTP and
fDPD, were superior to bone formation markers for the detection
of bone metastasis using ROC curve and T-score analysis. ICTP
showed promising results in the follow-up ofbone metastasis. The
present results strongly suggest that bone resorption markers are a
useful adjunct to bone scintigraphy in the diagnosis and follow-up
ofbone metastases from lung cancer.
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